Visit the SYMBODATM page to learn more about the technology behind the oral and transdermal investigational products currently being evaluated.
In July 2014, we temporarily suspended enrollment in the Spry Trial, and in October 2014, we temporarily stopped it in order to update the phase 3 protocol based on discussions with the FDA. We intend to update the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial.
- An investigational transdermal progesterone
- An investigational transdermal estradiol in combination with progesterone